In May 2026, Neurovalens announced that the U.S. Food and Drug Administration granted De Novo classification for Modius Spero, a prescribed wearable neuromodulation device for symptoms associated with post-traumatic stress disorder (PTSD). The Belfast-based company described it as the first device of its kind authorized in the U.S. for this use. Modius Spero uses low-level, non-invasive electrical stimulation and is indicated for adults aged 22 and older, with 30-minute daily sessions prescribed and overseen by a healthcare professional as part of a comprehensive care plan—not as a replacement for clinician-directed treatment.
Public materials reference a pivotal clinical study led by researchers including work at the University of California, San Diego, with 383 adults who had clinical PTSD diagnoses. Neurovalens reported that two-thirds of participants using Modius Spero showed clinically meaningful improvement in PTSD symptoms in that study; any outcomes discussion in sales conversations must stay within label and published evidence, not guaranteed results for every patient. Following the De Novo authorization, the company said Modius Spero is planned for availability to veterans through the U.S. Department of Veterans Affairs starting in summer 2026 (July cited in several releases). Neurovalens also markets other Modius devices—for example Modius Sleep and Modius Calm for veterans through the VA—under separate regulatory pathways; do not conflate those labels with Modius Spero’s PTSD indication.
For medical sales professionals, this is a wearable, prescription, home-use device story—not OR implants, cath lab capital, or traditional pharma detailing. The commercial motion spans behavioral health, psychiatry, primary care coordination, and government access channels (especially the VA), with heavy emphasis on onboarding, adherence, and claims discipline.
Why This Matters for Medical Sales Careers
- De Novo authorization creates a new regulatory category—adoption and hiring often trail evidence, access pathways, and operational readiness, not the press release date
- VA and federal channels add contracting, formulary-like dynamics, and longer stakeholder cycles than single-physician private practice selling
- Home-use wearables require reps who can support training, adherence, and escalation workflows—not just in-clinic demos
- Do not sell this like a psychiatry pharma brand; the buyer map, compliance rules, and ramp metrics differ
- Strong candidates combine digital health literacy (integration, documentation, realistic reimbursement talk) with relationship selling in mental health settings
Hiring and Interview Takeaways
Candidates should prepare examples of launching workflow change: clinician champions, pilot design, veteran- or community-facing programs, and expansion from early sites to broader access. Interviewers will care how you explain label scope, who approves new home-use therapies, and how you handled stalled pilots—not feature lists alone.
Employers hiring for neuromodulation or digital therapeutic territories should clarify VA versus commercial coverage, year-one utilization targets, and whether the role is launch-heavy or mixed with established lines. Reps from implant OR or cardio device backgrounds may ramp well on relationships but need coaching on behavioral health access and home-use adherence.